Prevalence of Acinetobacter baumannii Multidrug Resistance in University Hospital Environment.

IF 4.3 2区 医学 Q1 INFECTIOUS DISEASES
Francesco Foglia, Annalisa Ambrosino, Shahab Bashir, Emiliana Finamore, Carla Zannella, Giovanna Donnarumma, Anna De Filippis, Massimiliano Galdiero
{"title":"Prevalence of <i>Acinetobacter baumannii</i> Multidrug Resistance in University Hospital Environment.","authors":"Francesco Foglia, Annalisa Ambrosino, Shahab Bashir, Emiliana Finamore, Carla Zannella, Giovanna Donnarumma, Anna De Filippis, Massimiliano Galdiero","doi":"10.3390/antibiotics14050490","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b><i>Acinetobacter baumannii</i> is a significant pathogen and a major contributor to healthcare-associated infections, particularly in intensive care units. Its high potential for developing multiple drug resistance (MDR) makes it a challenging pathogen to manage. This study investigates the prevalence and resistance patterns of MDR <i>A. baumannii</i> isolates over a six-year period at a university hospital in Southern Italy. <b>Objective:</b> The aims of this study are to evaluate recent trends in the prevalence of MDR <i>A. baumannii</i>, analyze resistance patterns, and assess the impact of the antimicrobial diagnostic stewardship program implemented in 2018. <b>Methods:</b> This retrospective cohort study was conducted at the University Hospital of Campania \"Luigi Vanvitelli\" from 2018 to 2023. A total of 191 <i>A. baumannii</i> isolates from blood, urine, and wound samples were analyzed. Antimicrobial susceptibility testing was performed following EUCAST guidelines. The prevalence of MDR strains was assessed across three periods: pre-pandemic (2018-2019), during the pandemic (2020-2021), and post-pandemic (2022-2023) <b>Results:</b> Among the 191 isolates, 89.5% were classified as MDR. The highest number of isolates occurred in 2020, with blood cultures and urine samples increasing by 40.9% and 62.5%, respectively, while wound isolates decreased by 34.2%. The implementation of antimicrobial diagnostic stewardship programs correlated with a reduction in carbapenem resistance in 2020 and 2022. However, resistance to meropenem and colistin persisted. A 60.4% decline in total isolation from 2020 to 2023 suggests effective infection control measures. <b>Conclusions:</b> MDR <i>A. baumannii</i> remains a significant threat to healthcare. Although there have been slight reductions in resistance following antimicrobial stewardship interventions, persistent resistance to last-line antibiotics underscores the urgent need for alternative treatments, enhanced surveillance, and stricter infection control strategies.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"14 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12108267/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/antibiotics14050490","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background:Acinetobacter baumannii is a significant pathogen and a major contributor to healthcare-associated infections, particularly in intensive care units. Its high potential for developing multiple drug resistance (MDR) makes it a challenging pathogen to manage. This study investigates the prevalence and resistance patterns of MDR A. baumannii isolates over a six-year period at a university hospital in Southern Italy. Objective: The aims of this study are to evaluate recent trends in the prevalence of MDR A. baumannii, analyze resistance patterns, and assess the impact of the antimicrobial diagnostic stewardship program implemented in 2018. Methods: This retrospective cohort study was conducted at the University Hospital of Campania "Luigi Vanvitelli" from 2018 to 2023. A total of 191 A. baumannii isolates from blood, urine, and wound samples were analyzed. Antimicrobial susceptibility testing was performed following EUCAST guidelines. The prevalence of MDR strains was assessed across three periods: pre-pandemic (2018-2019), during the pandemic (2020-2021), and post-pandemic (2022-2023) Results: Among the 191 isolates, 89.5% were classified as MDR. The highest number of isolates occurred in 2020, with blood cultures and urine samples increasing by 40.9% and 62.5%, respectively, while wound isolates decreased by 34.2%. The implementation of antimicrobial diagnostic stewardship programs correlated with a reduction in carbapenem resistance in 2020 and 2022. However, resistance to meropenem and colistin persisted. A 60.4% decline in total isolation from 2020 to 2023 suggests effective infection control measures. Conclusions: MDR A. baumannii remains a significant threat to healthcare. Although there have been slight reductions in resistance following antimicrobial stewardship interventions, persistent resistance to last-line antibiotics underscores the urgent need for alternative treatments, enhanced surveillance, and stricter infection control strategies.

大学医院环境鲍曼不动杆菌多药耐药情况分析
背景:鲍曼不动杆菌是一种重要的病原体,也是卫生保健相关感染的主要原因,特别是在重症监护病房。其产生多重耐药(MDR)的高潜力使其成为一种具有挑战性的病原体。本研究调查了意大利南部一所大学医院六年多来耐多药鲍曼尼杆菌分离株的流行情况和耐药模式。目的:本研究的目的是评估耐多药鲍曼不动杆菌流行的最新趋势,分析耐药模式,并评估2018年实施的抗菌药物诊断管理计划的影响。方法:回顾性队列研究于2018 - 2023年在坎帕尼亚大学医院“Luigi Vanvitelli”进行。从血液、尿液和伤口样本中分离出191株鲍曼不动杆菌。抗菌药敏试验按照EUCAST指南进行。在流行前(2018-2019年)、流行期间(2020-2021年)和流行后(2022-2023年)三个时期对MDR菌株的流行情况进行了评估。结果:191株分离株中,89.5%被归类为MDR。分离株数量最多的年份是2020年,血培养和尿培养分别增加40.9%和62.5%,伤口分离株减少34.2%。抗菌药物诊断管理项目的实施与2020年和2022年碳青霉烯类耐药性的减少相关。然而,对美罗培南和粘菌素的耐药性持续存在。从2020年到2023年,总隔离人数下降60.4%,表明采取了有效的感染控制措施。结论:耐多药鲍曼杆菌仍然对医疗保健构成重大威胁。虽然在抗菌素管理干预措施后耐药性略有下降,但对最后一线抗生素的持续耐药性强调了迫切需要替代治疗、加强监测和更严格的感染控制战略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Antibiotics-Basel
Antibiotics-Basel Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
7.30
自引率
14.60%
发文量
1547
审稿时长
11 weeks
期刊介绍: Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信